Russia registered the world’s first vaccine against Covid-19 for animals, the country’s agriculture safety watchdog Rosselkhoznadzor said on March 31.
BioNTech and Pfizer will boost manufacturing capacity of their Covid-19 vaccine to 2.5 billion doses by the end of 2021, BioNTech said on March 30, as the company projected sales of nearly 10 billion euros ($11.7 billion) from the product during 2021.
The Covid-19 vaccines developed by Pfizer Inc. with BioNTech SE and Moderna Inc. are highly effective and reduced the risk of infection by 90 percent by two weeks after the second shot among healthcare personnel and first responders, according to a U.S. study released on March 29.
The U.S. government hit the accelerator on shipments of Covid-19 vaccines after a month of largely stagnant weekly deliveries, giving states the doses they say they need to finish vaccinating priority groups and open shots to all adults in the coming weeks.
The United States has administered 140,180,735 doses of Covid-19 vaccines and distributed 180,644,125 doses as of the morning of March 27, the U.S. Centers for Disease Control and Prevention said.
The U.S. government will distribute 11 million doses of Johnson & Johnson’s COVID-19 shot next week as the company continues to ramp up vaccine production to support the White House’s effort to get 200 million shots in arms in the first 100 days of President Biden’s term, a White House official said on March 26.
U.S. college students vaccinated with Moderna Inc.’s COVID-19 vaccine will be part of a new study to test mRNA-1273’s effectiveness in curbing the spread of the virus, the COVID-19 Prevention Network said on March 26.
One dose of Pfizer COVID-19 vaccine offers an immune response similar to that generated by infection and could also offer protection from variants to people who have previously had the virus, a British study said on March 26.
Several U.S. states on March 25 announced broad expansions of their Covid-19 vaccine rollouts, with California opening immunizations to all adults aged 50 and older starting April 1 and Florida making anyone 40 and up eligible from March 22.
AstraZeneca released primary analysis showing that the company’s AZD1222 vaccine demonstrated 76 percent efficacy against symptomatic Covid-19, 100 percent efficacy against severe or critical disease and hospitalizations, and 85 percent efficacy against symptomatic Covid-19 in people 65 years and older.